US4459279A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Retard form of pharmaceuticals with insoluble porous diffusion coatings
Assignee: Boehringer Ingelheim GmbH
•
Filing: 1982-08-18
•
Granted: 1984-07-10
•
Expires: 2002-08-18
Abstract
Abstract A pharmaceutical dosage unit retard form having a constant, pH-independent release rate of active ingredient, consisting of a core comprising an active ingredient, and a semi-permeable diffusion coating over the core, where the coating consists of a water-insoluble film-former, a water-soluble polymer and eventually an acid-insoluble polymer incorporated therein.
Inventors
- 👤 Herbert Stricker
- 👤 Bernhard Freund
- 👤 Heribert Harwalik
- 👤 Karl L. Rominger
- 👤 Siegfried Darda
- 👤 Volkmar Haselbarth
- 👤 Dietrich Arndts
- 👤 Wolf D. Bechtel
- 👤 Gerhard Bozler
- 👤 Rolf Brickl
- 👤 Peter Gruber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 09:41
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/55; A61K9/00; A61K9/20; A61K9/28; A61K9/2806; A61K9/2833; A61K9/2853; A61K9/286; A61K9/2866; A61K9/48; A61K9/4808
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
69 words
A pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing a plurality of non-disintegrating cores comprising mexiletine or an acid addition salt thereof, said cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the cores being at least about 5 mm.
Claim 2
Dependent Claim
69 words
A pharmaceutical dosage unit composition consisting essentially of a gelatin capsule containing a plurality of non-disintegrating cores comprising mexiletine or an acid addition salt thereof, said cores having a coating consisting of from 20 to 90 percent by weight of a water-insoluble film former and from 10 to 80 percent by weight of a water-soluble polymer, the diameter of each of the cores being at least about 5 mm.
Claim 3
Dependent Claim
23 words
The dosage unit composition of claim 1, wherein the mexiletine is present in a total amount of from about 0.1 to 1.5 gm.
Claim 4
Dependent Claim
15 words
The dosage unit composition of claim 1, wherein the water-insoluble film former is ethyl cellulose.
Claim 5
Dependent Claim
14 words
The dosage unit composition of claim 1, wherein the cores are tablets or pellets.
Claim 6
Dependent Claim
20 words
The dosage unit composition of claim 1, wherein the cores have a diameter of from about 5 to 6.2 mm.
Claim 7
Dependent Claim
31 words
A method for the treatment of cardiovascular disorders in a host in need of such treatment which comprises administering to said host an effective amount of a composition of claim 5.
References Cited (Backward Citations)
US2853420A
Cited
US2971889A
Cited
US2928770A
Cited
US3371015A
Cited
US3247066A
Cited
US3344029A
Cited
US3538214A
Cited
US3835221A
Cited
US3917813A
Cited
US4083949A
Cited
US4361546A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-10 | 1988-01-09 | 1988-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-10 | 1992-01-09 | 1992-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-10 | 1996-01-09 | 1996-07-10 | $7700.00 | Window Closed / Lapsed |